Understanding tumor localization in multiparametric MRI of the prostate-effectiveness of 3D printed models.
3D printed prostate model
MRI of the prostate
PI-RADS
prostate
prostate biopsy
prostate carcinoma
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
07
2023
accepted:
11
09
2023
medline:
6
10
2023
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
epublish
Résumé
Understanding tumor localization in multiparametric MRI (mpMRI) of the prostate is challenging for urologists but of great importance in mpMRI-fused prostate biopsy or radical prostatectomy. The aim was to evaluate the effectiveness of 3D printed models of the prostate to help urologists to locate tumors. 20 urologists from University Medical Center Mainz (Germany) were asked to plot the location of a cancer suspicious lesion (PI-RADS ≥ 4) on a total of 30 mpMRI on a prostate sector diagram. The following 3 groups (as matched triplets) were divided into: mpMRI only, mpMRI with radiological report and mpMRI with 3D printed model (scaled 1:1). Statistical analysis was performed using one-way and two-way ANOVA (with bonferroni post-test). Overall, localization of the suspicious lesion was superior with the radiological report (median of max. 10 [IQR]: MRI 2 [IQR 1;5], MRI + report: 8 [6.3;9], MRI + 3D model 3 [1.3;5.8]; Urologists still need the written radiological report for a sufficient understanding of tumor localization. The effectiveness of the 3D printed model regarding tumor localization is particularly evident in young residents (<1 year) and leads to a better overall assessment of the tumor extension.
Identifiants
pubmed: 37799119
doi: 10.3389/fsurg.2023.1264164
pmc: PMC10547869
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1264164Informations de copyright
© 2023 Haack, Reisen, Ghazy, Stroh, Frey, Sparwasser, Duwe, Mager, Haferkamp and Borgmann.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Urol. 2018 Oct;200(4):774-778
pubmed: 29679618
BJU Int. 2020 Jul;126(1):152-158
pubmed: 32219979
Int Urol Nephrol. 2017 Sep;49(9):1537-1544
pubmed: 28646483
Urol Int. 2015;95(4):465-71
pubmed: 26575991
Herz. 2013 Dec;38(8):862-7
pubmed: 24065050
3D Print Med. 2019 Feb 19;5(1):4
pubmed: 30783869
Transl Androl Urol. 2020 Apr;9(2):931-941
pubmed: 32420209
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Urology. 2021 Dec;158:150-155
pubmed: 34496263
Eur Urol. 2017 Aug;72(2):282-288
pubmed: 27574821
PLoS One. 2018 Jun 25;13(6):e0199477
pubmed: 29940018
Investig Clin Urol. 2021 Nov;62(6):658-665
pubmed: 34387041
Urology. 2019 Sep;131:40-45
pubmed: 31150691
Urologe A. 2022 Feb;61(2):133-141
pubmed: 34935997
JMIR Form Res. 2021 Oct 19;5(10):e20458
pubmed: 34665142
Urology. 2013 Nov;82(5):987-93
pubmed: 24055244
Eur Urol Focus. 2021 Nov;7(6):1274-1286
pubmed: 32873515
Eur Urol Focus. 2019 Jul;5(4):592-599
pubmed: 29226826
Arch Ital Urol Androl. 2021 Jun 28;93(2):139-142
pubmed: 34286544
Arch Ital Urol Androl. 2022 Sep 26;94(3):274-277
pubmed: 36165469
Curr Urol. 2018 Jun;11(4):182-188
pubmed: 29997460
Diagnostics (Basel). 2022 Nov 01;12(11):
pubmed: 36359499